Mallinckrodt

Mallinckrodt merged with Endo on July 31, 2025. By November 2025, the combined company had split into two independent entities: Keenova Therapeutics — the branded specialty-pharmaceuticals arm — and Par Health, the generics, sterile injectables, and API business. Both operate as separate companies under the Mallinckrodt parent.

Keenova concentrates on rare, stigmatized, and under-addressed conditions in immunology, urology, hepatology, ophthalmology, orthopedics, and critical care — a branded, innovation-driven model. Par Health is a scaled essential-medicine manufacturer producing high-volume generics, sterile injectables, and APIs, supported by a U.S.-advantaged manufacturing base with over 4,000 employees.

All available disclosures describe Mallinckrodt as a holding company for therapeutic operating businesses. No public evidence identifies a single-family-office mandate, a dedicated investment vehicle, or a wealth-management function. The entity appears to be an operating company, not a family office or asset manager in the traditional sense.

Par Health maintains a global workforce of over 4,000 team members, with manufacturing that the company describes as U.S.-advantaged. Keenova's geographic sales footprint has not been separately detailed, but the parent historically served international pharmaceutical markets.

No separate funds, co-investment vehicles, or third-party capital pools have been publicly disclosed. The structure is that of an operating parent with two wholly owned independent subsidiaries. No filings or firm statements reference an affiliated investment manager.